News

Biogasol attracts €15m
Enlarge image

FundingDenmarkCyprus

Biogasol attracts €15m

13.11.2012 - Danish Biogasol receives €15m equity and state money to test an lignocellulosic ethanol-production technology in a large-scale setting.

The renewable energy company BioGasol ApS from Ballerup has raised €15m. One third of the sum is new equity financing consisting of a co-investment by the current majority shareholder, Cyprus-based Fjord Capital Partners Ltd, and Unipension, a leading Danish pension fund managing assets of more than €12bn. €10m stems from a grant which has been approved by the Energy Technology Development and Demonstration Program (EUDP), a part of the Danish Energy Agency. BioGasol owns an appreciated, innovative pre-treatment reactor design for the cost-efficient and highly controlled conversion of lignocellulosic biomass into replacements for conventional fuels and other oil-based materials. The money is supposed to be used for transfering BioGasol's proprietary technology into demonstration scale. The large-scale testing plant will be built in Denmark starting in Q1/2013. "Our new demonstration facility will be co-financed by our industrial partners, SweetWater Energy in the US and a Scandinavian strategic partner," stated BioGasol's CEO Anders Weber.

Biogasol ApS is a Danish biotechnology company. Since its inception in 2006 as a spinout from the Technical University of Denmark, it already has successfully developed a pentose/hexose co-fermentation technology on pilot scale that makes use of metabolically engineered thermophilic bacteria. Biogasol develops so-called 2nd generation bioethanol by focussing on agricultural waste and wood as a source of lignocellulose.

Italian pioneer Chemtex group on the other hand is about to open a US bioethanol plant which will use non-food grasses grown on marginal land. Interestingly, Chemtex relies on the biomass processing enzymes produced by another Danish company, Novozymes. Biogasol is also uses some Novozymes enzymes. However, the company also owns proprietary and patented organisms like a heat-loving thermophilic bacterium isolated 20 years ago from a thermal spring in Iceland or a xylose-converting bacterium.

© eurobiotechnews.eu/ml

http://www.european-biotechnology-news.com/news/news/2012-04/biogasol-attracts-eur15m.html

SurveyGermany

06.05.2015 More revenue, more staff, more funding: in the German biotech industry, all signs are pointing towards growth.

M&ASwitzerland

04.05.2015 Swiss crop chemical maker Syngenta AG is in talks with US company Monsanto to discuss a possible merger, insiders say.

BiofuelsEU

30.04.2015 The European Parliament has given the go-ahead on a new law limiting the use of harmful crop-based biofuel in the transport sector. The decision marks a breakthrough in the EU’s approach to biofuels.

FinancingSwitzerlandUK

29.04.2015 Biopharma start-up CRISPR Therapeutics has raised US$64m to hurry the new CRISPR/Cas9 technology to the clinic.

FinancingBelgium

28.04.2015 After having raised €100m in its stock market debut, MDx company Biocartis has gained 13 percent on its first trading day.

Swiss Biotech DaySwitzerland

16.04.2015 The Swiss biotech industry can look back on 2014 as a good year, but political uncertainties do remain. This was one of the topics discussed during the Swiss Biotech Day in Basel, which attracted more than 400 participants.

FinancingUK

21.04.2015 Ahead of its listing on the London Stock Exchange, Woodford’s Patient Capital Trust has raised a record sum of €1.1bn. The fund met with immense interest by investors.

PoliticsEU

22.04.2015 A legislative proposal by the European Commission is set to renationalise market authorisation of genetically modified crops.

EventEUFrance

16.04.2015 The changing landscape in healthcare was just one of the hotly discussed topics of the 27th Annual EuroMeeting of the international association DIA.

R&DFranceUKSweden

24.04.2015 AstraZeneca has boosted its oncology portfolio by signing a US$1.275bn agreement with Innate Pharma. The companies plan to further the development of Innate’s tumour-targeting antibody.

Events

All Events

Partner-Events

München

BioVaria 2015

Current issue

All issues

Product of the week

Products

Stock list

All quotes

TOP

  • 4SC5.41 EUR4.04%
  • WILEX5.25 EUR3.35%
  • BIOFRONTERA2.34 EUR1.74%

FLOP

  • VITA 345.86 EUR-6.69%
  • FORMYCON26.31 EUR-6.04%
  • MORPHOSYS63.42 EUR-6.02%

TOP

  • 4SC5.41 EUR322.7%
  • WILEX5.25 EUR83.6%
  • PAION2.85 EUR21.3%

FLOP

  • BIOTEST72.00 EUR-25.9%
  • THERAMETRICS0.07 CHF-22.2%
  • MEDIGENE10.16 EUR-17.6%

TOP

  • SANTHERA96.00 CHF2361.5%
  • CYTOS1.27 CHF647.1%
  • WILEX5.25 EUR517.6%

FLOP

  • MOLOGEN4.85 EUR-55.5%
  • THERAMETRICS0.07 CHF-30.0%
  • BIOFRONTERA2.34 EUR-26.6%

No liability assumed, Date: 05.05.2015